SCHEMBL24449244

SCHEMBL24449244

CN1CCN(Cc2ccc(NC(=O)Nc3cc(-c4ccc(-c5cnc6cccnn56)cc4)n(C)n3)cc2C(F)(F)F)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 16/20 0.75
▸ ABL2 P42684 8/20 0.75
▸ MAPK14 Q16539 4/20 0.75
▸ BCR P11274 2/20 0.57
▸ NTRK1 P04629 3/20 0.56
▸ SRC P12931 3/20 0.56
▸ FGFR4 P22455 2/20 0.56
▸ GAK O14976 1/20 0.56
▸ MLNR O43193 1/20 0.56
▸ RIPK2 O43353 1/20 0.56
▸ JAK2 O60674 1/20 0.56
▸ NR1I2 O75469 1/20 0.56
▸ ABCB11 O95342 1/20 0.56
▸ MAP4K4 O95819 1/20 0.56
▸ EGFR P00533 1/20 0.56
▸ NR3C1 P04150 1/20 0.56
▸ ERBB2 P04626 1/20 0.56
▸ LCK P06239 1/20 0.56
▸ FYN P06241 1/20 0.56
▸ PGR P06401 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19317716 0.95 ABL1 (0.78) ABL1ABL2MAPK14BCRNTRK1
SCHEMBL24449265 0.92 ABL1 (0.72) ABL1ABL2MAPK14BCRNTRK1
SCHEMBL19316720 0.88 ABL1 (0.75) ABL1ABL2MAPK14BCRSRC
SCHEMBL24448254 0.86 ABL1 (0.70) ABL1ABL2MAPK14NTRK1SRC
SCHEMBL19317673 0.86 ABL1 (1.00) ABL1ABL2MAPK14BCRNTRK1
SCHEMBL19317707 0.85 ABL1 (0.64) ABL1ABL2MAPK14SRCFGFR4
SCHEMBL24449268 0.84 ABL1 (0.59) ABL1ABL2MAPK14SRCFGFR4
SCHEMBL19316705 0.83 ABL1 (0.71) ABL1ABL2MAPK14BCRNTRK1
SCHEMBL19317715 0.83 ABL1 (0.75) ABL1ABL2MAPK14SRCFGFR4
SCHEMBL24448260 0.83 ABL1 (0.73) ABL1ABL2MAPK14NTRK1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 ABL1 4516/4885ABL2 2755/4885MAPK14 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback